During the most recent trading day, the stock’s price shifted up + 1.27 percent from its 52-week-low while -75.09 percent lower from its 52-week high.
Valeant Pharmaceuticals Intl Inc generated a return on investment of -1.60% in past 12 months and return on equity of -52.70% for similar period.
The share price of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) declined -71.52 percent for the year. YTD, the current share price of the stock is below -33.95 percent. Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
According to Channel NewsAsia, Dalian Wanda Group Co Ltd will invest 70 billion yuan (US$10 billion) in a health park in China’s southwest, the firm said in a statement sent to Reuters on Monday, as some of the country’s biggest companies look to tap demand for private healthcare.
Wanda, headed by China’s richest man, Wang Jianlin, said it had signed an agreement with the Chengdu city government to create a ‘park’ with two international general hospitals, eight small specialized hospitals and 30 healthcare-related firms.
The investment comes as China’s public hospitals are facing tough demands from a fast-ageing population and tightening budgets as the government looks to reduce state hospitals’ reliance on drug sales. This is creating space for private firms. Source: NewsAsia
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) declined 0.42% to $9.59 on Friday. The share price is trading in a range of 9.44 – 9.80 (Price in Dollars). The stock exchanged hands with 16,267,735 shares contrast to its average daily volume of 19,645,424 shares.